Endometrial carcinosarcoma
Giorgio Bogani, Isabelle Laure Ray-Coquard, Nicole Concin et al. · International Journal of Gynecological Cancer · 2022
Cited by 99 works. doi:10.1136/ijgc-2022-004073 Open-access PDF
Authors
- Giorgio Bogani
- Isabelle Laure Ray-Coquard
- Nicole Concin
- Natalie Y.L. Ngoi
- Philippe Morice
- Giuseppe Caruso
- Takayuki Enomoto
- Kazuhiro Takehara
- Hannelore G Denys
- Domenica Lorusso
- Robert Louis Coleman
- Michelle Margaret Vaughan
- Masashi Takano
- Diane Michele Provencher
- Satoru Sagae
- Pauline Wimberger
- Ròbert Póka
- Yakir Segev
- Se Ik Kim
- Jae‐Weon Kim
References
- Cancer statistics, 2022
- Integrated genomic characterization of endometrial carcinoma
- ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
- A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study
- Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer
- Confirmation of ProMisE: A simple, genomics‐based clinical classifier for endometrial cancer
- Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: An European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874)
- Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study
- Endometrial Cancer
- Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study.